期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

R-CHOP方案治疗Ⅲ～Ⅳ期老年DLBCL的临床疗效及耐受性分析 被引量：5

R-CHOP regimen for elderly patients with Ⅲ～Ⅳ stage DLBCL
暂未订购
导出
摘要 目的探讨R-CHOP方案(利妥昔单抗、环磷酰胺、表柔比星、长春新碱、泼尼松龙)在Ⅲ～Ⅳ期≥60岁老年弥漫大B细胞淋巴瘤中的疗效及安全性。方法收集≥60岁的Ⅲ～Ⅳ期弥漫大B细胞淋巴瘤患者33例,行R-CHOP 3周方案化疗6疗程,观察治疗反应率、生存率以及相关不良反应。结果全组33例患者中,25例(75.8%)完成6疗程化疗,完全缓解(complete remission,CR)及不确定完全缓解(unconfirmed complete remission,uCR)12例(36.4%)。总有效率(完全缓解或部分缓解)为81.8%(27/33)。全组中位随访时间为25.2月(2.0-77.6月),2年总生存率为51.2%,2年无进展生存率为39.4%,2年无事件生存率为38.6%。截至随访结束,15例生存,12例(36.4%)为无瘤生存。治疗过程中2例(6.1%)因治疗相关感染死亡,>1/3的患者曾出现Ⅲ～Ⅳ级的骨髓抑制。单因素及多因素分析发现,近期疗效为CR的患者预后明显好于其他患者。结论足量的R-CHOP化疗在≥60岁老年Ⅲ～Ⅳ期弥漫大B细胞淋巴瘤患者中有较好的耐受性、安全性和有效率。但疗效持续时间短,其长期疗效仍不理想。 Objective To investigate the efficacy and safety of R-CHOP regimen（ rituximab, cyclophosphamide, epirubicin, vincristine, prednisolone） for elderly patients with stage Ⅲ ～ Ⅳ diffuse large B-cell lymphoma（ DLBCL）.Methods Thirty-three patients aged ≥60 y diagnosed as stage Ⅲ ～ Ⅳ DLBCL were recruited consecutively. Six cycles of R-CHOP chemotherapy were planned. The response to treatment,treatment-related toxicity and survival of patients were analyzed. Results Twenty five out of 33 patients（ 75. 8%） completed the full cycles of chemotherapy,and 12 cases（ 36.4%） obtained complete remission（ CR） or unconfirmed complete remission（ uCR）. The overall response rate was81. 8%（ 27 /33）. Patients were followed up for a medium of 25. 2 months（ 2. 0- 77. 6 months）. Two-y overall survival（ OS）,2-y progression-free survival（ PFS） and 2-y event-free survival（ EFS） were 51.2%,39.4% and 38.6%,respectively. Fifteen patients survived. Twelve patients（ 36. 4%） survived with CR up to last follow-up and 2 patents（ 6.1%） died from treatment-related infection. Ⅲ ～ Ⅳ myelosuppression was found in over one-third of the patients.Univariate and multivariate analysis showed that superior survival was observed in patients who obtained complete remission in first-line chemotherapy. Conclusion High response rate and safety can be obtained for elderly Ⅲ ～ Ⅳ stage DLBCL patients with full dose R-CHOP regimen.
作者 施展 沈倩雯 王静文 唐曦
机构地区 复旦大学附属华东医院肿瘤内科 复旦大学附属华东医院放疗科
出处 《实用肿瘤杂志》 CAS 2014年第4期330-335,共6页 Journal of Practical Oncology
关键词 淋巴瘤 大B细胞 弥漫性 药物疗法 长春新碱 投药和剂量 多柔比星 投药和剂量 抗体 单克隆 治疗应用 抗肿瘤联合化疗方案 治疗应用 治疗结果 存活率 老年人 lymphoma large B-cell diffuse/drug therapy vincristine/administration ＆ dosage doxorubicin/administration ＆ dosage antibodies monoclonal/therapeutic use antineoplastic combined chemotherapy protocols/therapeutic use treatment outcome survival rate aged
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1Coiffier B. Non-Hodgkin's lymphomas [ M ]//Cavalli F, Hansen HH, Kaye SB. Textbook of medical oncology. London : Martin Dunitz, 1997:265 - 287.
  • 2Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy[ J]. J Clin Oncol, 1995,13 (10) : 2530 - 2539.
  • 3Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients 70 years of age with intermediate-grade and high-grade non-Hodgkin's lym- phoma:results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group [ J]. J Clin Oncol, 1998,16( 1 ) :27 - 34.
  • 4Sonnen R, Schmidt WP, Kuse R, et al. Treatment results of aggressive B non-Hodgkin's lymphoma in advanced age considering comorbidity [ J ]. Br J Haematol, 2002, 119 (3) :634 -639.
  • 5Trotti A, Colevas AD, Setser A, et al. CTCAE v3. 0: development of a comprehensive grading system for the adverse effects of cancer treatment [ J ]. Semin Radiat Onco1,2003,13 ( 3 ) : 176 - 181.
  • 6Cheson BD, Pfistner B, Juweid ME. Revised response criteria for malignant lymphoma[ J]. Clin Oncol,2007,25 (5) :579 -586.
  • 7Salvi F, Miller MD, Grilli A. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients [ J ]. J Am Geriatr Soc,2008,56(10) : 1926 - 1931.
  • 8Coiffier B, Thieblemont C, Van Den Neste E. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Aduhe [ J ]. Blood, 2010,116(12) :2040-2045.
  • 9Kreher S, Lammer F, Augustin D, et al. R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma[ J ]. Eur J Haematol, 2014, doi : 10. 1111/ejh. 12304. [ Epub ahead of print].
  • 10Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elder- ly patients older than 80 years with diffuse large B-cell lymphoma : a multicentre, single-arm, phase 2 trial [ J ]. Lancet Onco1,2011,12 (5) :460 - 468.

同被引文献69

引证文献5

二级引证文献19

实用肿瘤杂志
2014年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部